Use of cilostazol in percutaneous coronary interventions (Q38016384)

27 August 2017

title

Use of cilostazol in percutaneous coronary interventions (English)

1 reference

27 August 2017

Kelly C Rogers

1

1 reference

27 August 2017

Jenna M Faircloth

series ordinal

2

1 reference

27 August 2017

Shannon W Finks

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

5 June 2012

1 reference

Annals of Pharmacotherapy

27 August 2017

published in

1 reference

27 August 2017

volume

46

1 reference

27 August 2017

issue

6

1 reference

27 August 2017

page(s)

839-850

1 reference

27 August 2017

cites work

Clopidogrel resistance?

1 reference

High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome

21 January 2018

1 reference

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 January 2018

1 reference

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thro

21 January 2018

1 reference

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials

21 January 2018

1 reference

In-stent restenosis in the drug-eluting stent era.

21 January 2018

1 reference

Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells

21 January 2018

1 reference

Comparison of cilostazol versus ticlopidine therapy after stent implantation

21 January 2018

1 reference

Comparison of cilostazol and clopidogrel after successful coronary stenting

21 January 2018

1 reference

Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial)

21 January 2018

1 reference

Coronary stent restenosis in patients treated with cilostazol

21 January 2018

1 reference

The pharmacology of cilostazol

21 January 2018

1 reference

Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting

21 January 2018

1 reference

Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting St

21 January 2018

1 reference

Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).

21 January 2018

1 reference

Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis

21 January 2018

1 reference

Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study.

21 January 2018

1 reference

Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study

21 January 2018

1 reference

Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy

21 January 2018

1 reference

Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial

21 January 2018

1 reference

A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.

21 January 2018

1 reference

Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

21 January 2018

1 reference

Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

21 January 2018

1 reference

Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance

21 January 2018

1 reference

Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

21 January 2018

1 reference

Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidog

21 January 2018

1 reference

Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Pati

21 January 2018

1 reference

Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1Q765

1 reference

release_wlpn4w45ovdmzemhwtfbjqlhqi

27 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wlpn4w45ovdmzemhwtfbjqlhqi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference